• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Bausch + Lomb to acquire Technolas Perfect Vision

Bausch + Lomb to acquire Technolas Perfect Vision

November 9, 2012
CenterWatch Staff

Bausch + Lomb, a global eye health company, has exercised its option to purchase all outstanding and unowned shares of Technolas Perfect Vision (TPV), a ophthalmology laser company based in Germany.

Technolas Perfect Vision was established in 2009 through a joint venture between Bausch + Lomb and 20/10 Perfect Vision to develop and sell advanced refractive and cataract technologies. The deal is expected to close at the end of January 2013.

Bausch + Lomb and Technolas Perfect Vision entered into a co-promotion agreement back in September 2011, which also included an option for Bausch + Lomb to purchase the company if certain key milestones were achieved. Since that time, the companies have leveraged their combined cataract and refractive expertise and commercial capabilities to promote and further advance the Victus femtosecond laser, which is capable of supporting cataract and corneal procedures on a single platform. In the last 12 months, the Victus platform received marketing approval from regulatory authorities in Europe and the U.S., and the companies are continuing to file registrations in other parts of the world as they accelerate the roll-out.

"Our acquisition of Technolas Perfect Vision represents an important milestone for Bausch + Lomb, but perhaps more importantly, for cataract and refractive patients worldwide," said Brent Saunders, president and CEO, Bausch + Lomb. "The Technolas Perfect Vision team has built a great company and from my perspective, the most innovative ophthalmic lasers in the industry."

Kristian Hohla, Ph.D., CEO of Technolas Perfect Vision, said, "Our systems for refractive and cataract procedures complement Bausch + Lomb's surgical portfolio and will help accelerate our expansion into the faster growing segments of the ocular surgery market. Together, we've proven our ability to introduce and market the highly innovative and differentiated Victus Femtosecond Laser Platform, and we look forward to working with our Bausch + Lomb colleagues to further advance ocular surgery using other laser-based technologies."

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing